文献速递白血病

将索拉非尼纳入老年FLT3突变急性髓系白血病化疗的2期研究:CALGB 11001

A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001.
PubMed 文献 · Blood Adv · 2017-01-01

CALGB开展的多中心单臂2期研究,在≥60岁FLT3突变急性髓系白血病患者中,将索拉非尼加入柔红霉素和阿糖胞苷为基础的诱导和巩固化疗,并维持治疗12个月。FLT3-ITD组1年总生存率为62%(95%CI 45%-78%),达到主要终点(对比历史对照组30%,P<.0001);FLT3-TKD组为71%(95%CI 42%-92%)。研究提示该方案可行,可能改善老年FLT3突变患者的生存。

要点

  • FLT3-ITD组1年总生存率62%,达到主要终点(历史对照30%,P<.0001)
  • FLT3-ITD组中位无病生存12.2个月,中位总生存15.0个月
  • FLT3-TKD组1年总生存率71%,中位无病生存9.6个月,中位总生存16.2个月

核心结论

  • 在FLT3-ITD急性髓系白血病老年患者中,将索拉非尼加入化疗是可行的,可能改善老年FLT3突变患者的生存。

研究设计与样本

  • CALGB(现为肿瘤临床试验联盟的一部分)开展的多中心、单臂、2期研究,纳入年龄≥60岁的FLT3突变急性髓系白血病患者。
  • 索拉非尼加入柔红霉素和阿糖胞苷为基础的诱导和巩固化疗,并继续维持治疗12个月。
  • 主要终点为FLT3-ITD队列的1年总生存率;共入组54例患者,中位年龄67岁(范围60.3-82.7岁),其中FLT3-ITD患者39例(71%),FLT3-TKD患者15例(29%)。

主要发现

  • FLT3-ITD患者1年总生存率为62%(95%CI 45%-78%),达到主要终点(对比历史对照组30%,P<.0001)。
  • FLT3-TKD患者1年总生存率为71%(95%CI 42%-92%)。
  • FLT3-ITD组中位无病生存为12.2个月(95%CI 5-16.9),中位总生存为15.0个月(95%CI 10.4-20.1)。
  • FLT3-TKD组中位无病生存为9.6个月(95%CI 1.9至不可评估[NA]),中位总生存为16.2个月(95%CI 5.0至NA)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Cancer and Leukemia Group B (CALGB), now part of the Alliance for Clinical Trials in Oncology, conducted a multicenter, single-arm, phase 2 study in patients ≥60 years with FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML). In this study, sorafenib was added to daunorubicin and cytarabine-based induction and consolidation chemotherapy and was also continued for 12 months of maintenance therapy. The primary end point of the study was overall survival (OS) at 1 year in the FLT3 internal tandem duplication (FLT3-ITD) cohort. Fifty-four patients with a median age of 67 years (range, 60.3-82.7 years) were enrolled; 39 were FLT3-ITD patients (71%) and 15 were FLT3-TKD (29%) patients. The observed 1-year OS (95% confidence interval [CI]) was 62% (45%-78%) for the FLT3-ITD patients (meeting the primary end point 62% vs 30% for a historical control group, P < .0001) and 71% (42%-92%) for the FLT3-TKD patients. The median disease-free survival and OS were 12.2 months (95% CI, 5-16.9) and 15.0 months (95% CI, 10.4-20.1), respectively, in the FLT3-ITD group and 9.6 (95% CI, 1.9 to not available [NA]) and 16.2 months (95% CI, 5.0 to NA) for the FLT3-TKD group. This study suggests that the addition of sorafenib to chemotherapy for FLT3-ITD AML is feasible and may improve the survival of older adults with FLT3-mutated AML. This trial was registered at www.clinicaltrials.gov as #NCT01253070.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Uy GL, Mandrekar SJ, Laumann K, et al. A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv. 2017. PMID: 29034366. doi:10.1182/bloodadvances.2016003053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。